Karen Tepichin is the General Counsel of Ginkgo Bioworks Holdings, Inc., a Boston-based biotechnology company that went public in 2021. Ginkgo builds the tools that make biology easier to engineer for everyone. Ginkgo R&D Solutions delivers customizable R&D packages—such as protein engineering, nucleic acid design, and cell-free systems—giving partners a comprehensive way to accelerate innovation across therapeutics, diagnostics, & manufacturing. Ginkgo Automation sells modular, integrated laboratory automation so scientists can spend their days planning and analyzing experiments rather than pipetting in the lab. Ginkgo Datapoints uses Ginkgo’s in-house automation to generate the large lab datasets to power your AI models. Ginkgo Biosecurity is building and deploying the next-generation infrastructure and technologies that global leaders need to predict, detect, and respond to a wide variety of biological threats. Prior to joining Ginkgo, Karen was a partner at Foley Hoag in Boston.
